explore -WSS

explore

author：fashion 2025-08-26 23:48:55 - browse：24

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Search warrant issued in 1996 disappearance of Kristin Smart

focus

WSS

Menendez indictment could see pharma lose a key ally

Mindstrong's demise and the future of mental health care

Address the ethical violations that led to 'Three Identical Strangers'

Condition critical? Britain's beloved but battered National Health Service turns 75

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

Why do women spend more than men on medical expenses?

focus

explore

entertainment

In age of alternative facts, a scholarly course on calling out crap

Ionis has late

Hepatitis C has a cure — but many Americans still lack access to it

Senator probes 340B programs at Cleveland Clinic, Bon Secours

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Tori Bowie and the unacceptable rates of Black maternal death

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Medical records are filled with copy

Address the ethical violations that led to 'Three Identical Strangers'

leisure time

WHO recommends dropping component of many flu vaccines

A bus careens into a gulch in southern Mexico, leaving 27 people dead

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

Pentagon will tighten controls on classified information after Discord leak

explore

hotspot

focus

leisure time